eli lilly retatrutide clinical trials orforglipron oral GLP-1 phase 3 weight loss trial Eli Lilly infiltrates anti-obesity market
Description
NPs serve as versatile drug carriers that can be functionalized with targeting components to direct drug delivery to specific tissues or cell types, thereby enhancing drug accumulation at desired sites [76,77]
Sounds great for some things, right
The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage
Treatment will need to be chronic
